{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:04:04Z","timestamp":1789790644670,"version":"4.0.1"},"reference-count":36,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,18]]},"DOI":"10.1248\/bpb.b26-00243","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:12:05Z","timestamp":1789683125000},"page":"1529-1537","source":"Crossref","is-referenced-by-count":0,"title":["Simple LC-MS\/MS Method for Ruxolitinib in Human Plasma and Its Clinical Application in Pediatric and Adult Patients"],"prefix":"10.1248","volume":"49","author":[{"given":"Atsushi","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tazawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nashimoto","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060\u20138638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyo","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kagami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Faculty of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060\u20138638, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo 060\u20138648, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) O\u2019Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. <i>Immunity<\/i>, <b>36<\/b>, 542\u2013550 (2012).","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Verstovsek S, Mesa RA, Gotlib J, <i>et al<\/i>. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>N. Engl. J. Med.<\/i>, <b>366<\/b>, 799\u2013807 (2012).","DOI":"10.1056\/NEJMoa1110557"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib <i>versus<\/i> standard therapy for the treatment of polycythemia vera. <i>N. Engl. J. Med.<\/i>, <b>372<\/b>, 426\u2013435 (2015).","DOI":"10.1056\/NEJMoa1409002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Soci\u00e9 G. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. <i>N. Engl. J. Med.<\/i>, <b>382<\/b>, 1800\u20131810 (2020).","DOI":"10.1056\/NEJMoa1917635"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. <i>N. Engl. J. Med.<\/i>, <b>385<\/b>, 228\u2013238 (2021).","DOI":"10.1056\/NEJMoa2033122"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad A, Diaz-de-Heredia C. Ruxolitinib for pediatric patients with treatment-na\u00efve and steroid-refractory acute graft-versus-host disease: the REACH4 study. <i>Blood<\/i>, <b>144<\/b>, 2095\u20132106 (2024).","DOI":"10.1182\/blood.2023022565"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, G\u00fcng\u00f6r T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. <i>Lancet Haematol.<\/i>, <b>11<\/b>, e580\u2013e592 (2024).","DOI":"10.1016\/S2352-3026(24)00174-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Takahashi S, Hashimoto D. Recent advances in the pathophysiology of acute and chronic graft-versus-host disease. <i>Int. J. Hematol.<\/i>, <b>123<\/b>, 792\u2013801 (2026).","DOI":"10.1007\/s12185-026-04177-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) De Togni E, Cole O, Abboud R. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. <i>Front. Immunol.<\/i>, <b>15<\/b>, 1304065 (2024).","DOI":"10.3389\/fimmu.2024.1304065"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. <i>Int. J. Hematol.<\/i>, <b>120<\/b>, 106\u2013116 (2024).","DOI":"10.1007\/s12185-024-03772-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yang Y, Huo Y, Zhou D, Kang Z, Huang Y, Wang Y, Fan G, Ma L, Yan J. Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience. <i>Front. Immunol.<\/i>, <b>16<\/b>, 1621708 (2025).","DOI":"10.3389\/fimmu.2025.1621708"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Baccelli F, Gottardi F, Muratore E, Leardini D, Grasso AG, Gori D, Belotti T, Prete A, Masetti R. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. <i>Bone Marrow Transplant.<\/i>, <b>59<\/b>, 765\u2013776 (2024).","DOI":"10.1038\/s41409-024-02252-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zhang Q, Zhao Y-Z, Ma H-H, Wang D, Cui L, Li WJ, Wei A, Wang CJ, Wang TY, Li ZG, Zhang R. A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. <i>Blood<\/i>, <b>139<\/b>, 3493\u20133504 (2022).","DOI":"10.1182\/blood.2021014860"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ogama Y, Mineyama T, Yamamoto A, Woo M, Shimada N, Amagasaki T, Natsume K. A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. <i>Int. J. Hematol.<\/i>, <b>97<\/b>, 351\u2013359 (2013).","DOI":"10.1007\/s12185-013-1280-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. <i>J. Clin. Pharmacol.<\/i>, <b>51<\/b>, 1644\u20131654 (2011).","DOI":"10.1177\/0091270010389469"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: A review. <i>Clin. Pharmacokinet.<\/i>, <b>62<\/b>, 559\u2013571 (2023).","DOI":"10.1007\/s40262-023-01225-7"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Merienne C, Rousset M, Ducint D, Castaing N, Titier K, Molimard M, Bouchet S. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS\/MS. <i>J. Pharm. Biomed. Anal.<\/i>, <b>150<\/b>, 112\u2013120 (2018).","DOI":"10.1016\/j.jpba.2017.11.060"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Pressiat C, Huynh HH, Pl\u00e9 A, Sauvageon H, Madelaine I, Chougnet C, Le Maignan C, Mourah S, Goldwirt L. Development and validation of a simultaneous quantification method of ruxolitinib, vismodegib, olaparib, and pazopanib in human plasma using liquid chromatography coupled with tandem mass spectrometry. <i>Ther. Drug Monit.<\/i>, <b>40<\/b>, 337\u2013343 (2018).","DOI":"10.1097\/FTD.0000000000000497"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Koller D, Vaitsekhovich V, Mba C, Steegmann JL, Zubiaur P, Abad-Santos F, Wojnicz A. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS\/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. <i>Talanta<\/i>, <b>208<\/b>, 120450 (2020).","DOI":"10.1016\/j.talanta.2019.120450"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Aghai F, Zimmermann S, Kurlbaum M, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma. <i>Anal. Bioanal. Chem.<\/i>, <b>413<\/b>, 599\u2013612 (2021).","DOI":"10.1007\/s00216-020-03031-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Llopis B, Robidou P, Tissot N, Pinna B, Gougis P, Aubart FC, Campedel L, Abbar B, Weil DR, Uzunov M, Gligorov J, Salem JE, Funck-Brentano C, Zahr N. Development and clinical validation of a simple and fast UPLC-ESI-MS\/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>J. Pharm. Biomed. Anal.<\/i>, <b>197<\/b>, 113968 (2021).","DOI":"10.1016\/j.jpba.2021.113968"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Tachet J, Versace F, Mercier T, Buclin T, Decosterd LA, Choong E, Girardin FR. Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma. <i>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.<\/i>, <b>1230<\/b>, 123917 (2023).","DOI":"10.1016\/j.jchromb.2023.123917"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kumondai M, Hayashi N, Sato Y, Kobayashi D, Otsuki A, Ueki Y, Onishi Y, Tsukamoto T, Yoshikawa K, Hayakawa Y, Sato Y, Sato T, Sato M, Kikuchi M, Maekawa M, Mano N. Development and clinical application of a simultaneous liquid chromatography-tandem mass spectrometry method for patients with graft-versus-host disease to quantify the plasma concentrations of ruxolitinib and posaconazole. <i>Biol. Pharm. Bull.<\/i>, <b>49<\/b>, 301\u2013309 (2026).","DOI":"10.1248\/bpb.b25-00646"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Zhao Y, Chen P, Dou L, Li F, Li M, Xu L, Chen J, Jia M, Huang S, Wang N, Luan S, Yang J, Bai N, Liu D. Co-administration with voriconazole doubles the exposure of ruxolitinib in patients with hematological malignancies. <i>Drug Des. Devel. Ther.<\/i>, <b>16<\/b>, 817\u2013825 (2022).","DOI":"10.2147\/DDDT.S354270"},{"key":"25","unstructured":"25) FDA. \u201cBioanalytical method validation guidance for industry.\u201d: \u2039https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry\u203a, accessed 15 October, 2024."},{"key":"26","unstructured":"26) EMA. \u201cGuideline on bioanalytical method validation.\u201d: \u2039https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation-scientific-guideline\u203a, accessed 15 October, 2024."},{"key":"27","unstructured":"27) ICH. \u201cBioanalytical method validation and study sample analysis M10\u201d: \u2039https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf\u203a, accessed 15 October, 2024."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Zimmermann S, Aghai F, Schilling B, Kraus S, Grigoleit GU, Kalogirou C, Goebeler M-E, Jung P, Pelzer T, Klinker H, Isberner N, Scherf-Clavel O. Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their <i>in vitro<\/i> VAMS-to-plasma ratio. <i>J. Pharm. Biomed. Anal.<\/i>, <b>211<\/b>, 114623 (2022).","DOI":"10.1016\/j.jpba.2022.114623"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Li N, Zhang H, Bai H, Lu K. Development and validation of an LC-MS\/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies. <i>J. Pharm. Pharm. Sci.<\/i>, <b>27<\/b>, 12905 (2024).","DOI":"10.3389\/jpps.2024.12905"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Li Z, Sun N, Zhang Q, Ma HH, Wang D, Zhao YZ, Yang CQ, Zhang R, Zhao LB. Development and application of an LC-MS\/MS method for pharmacokinetic study of ruxolitinib in children with hemophagocytic lymphohistiocytosis. <i>Anal. Methods<\/i>, <b>14<\/b>, 2293\u20132303 (2022).","DOI":"10.1039\/D2AY00533F"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Cook E, Dong M, Chiang SCC, Luedeke D, Lake KE, Hoerth C, Deavy M, Setchell KDR, Zhao J, Punt N, Galletta T, Teusink-Cross A, Davies SM, Marsh RA, Mehta P, Khandelwal P. Ruxolitinib pharmacokinetics and pharmacodynamics in children with acute and chronic graft-versus-host disease. <i>Transplant. Cell. Ther.<\/i>, <b>30<\/b>, 528.e1\u2013528.e12 (2024).","DOI":"10.1016\/j.jtct.2024.02.018"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, Landman RR, McKeever EG Jr, Punwani NG, Williams WV, Yeleswaram S. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J. Clin. Pharmacol.<\/i>, <b>52<\/b>, 809\u2013818 (2012).","DOI":"10.1177\/0091270011405663"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Aslanis V, Umehara K, Huth F, Ouatas T, Bharathy S, Butler AA, Zhou W, Gadbaw B. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. <i>Cancer Chemother. Pharmacol.<\/i>, <b>84<\/b>, 749\u2013757 (2019).","DOI":"10.1007\/s00280-019-03907-1"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. A physiologically-based pharmacokinetic model of ruxolitinib and posaconazole to predict CYP3A4-mediated drug-drug interaction frequently observed in graft <i>versus<\/i> host disease patients. <i>Pharmaceutics<\/i>, <b>14<\/b>, 2556 (2022).","DOI":"10.3390\/pharmaceutics14122556"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O. Ruxolitinib exposure in patients with acute and chronic graft <i>versus<\/i> host disease in routine clinical practice-a prospective single-center trial. <i>Cancer Chemother. Pharmacol.<\/i>, <b>88<\/b>, 973\u2013983 (2021).","DOI":"10.1007\/s00280-021-04351-w"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Mahmoudjafari Z, Kintsch E, Xue Z, Bhatt V, Galvin J, Locatelli F, Zeiser R. Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: <i>post hoc<\/i> analyses of REACH2 and REACH3. <i>Blood Adv.<\/i>, <b>9<\/b>, 4206\u20134216 (2025).","DOI":"10.1182\/bloodadvances.2025016212"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00243\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:27:50Z","timestamp":1789788470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00243\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00243","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"b26-00243"}}